27 In the 2014-2015 influenza season a novel neuraminidase (NA) genotype emerged in 28 the Johns Hopkins Center of Excellence for Influenza Research and Surveillance (JH 29 CEIRS) surveillance network as well as globally. This novel genotype encoded a 30 glycosylation site at position 245-247 in the NA protein from clade 3c.2a H3N2 viruses.
161 sialic acid [29] . Both viruses showed similar kinetics of infectious virus production and 162 peak infectious virus amounts after a low MOI infection ( Fig 1A) . In contrast, infection of 163 hNEC cultures at a low MOI with the 245 NA Gly-virus yielded significantly higher 164 amounts of infectious virus for a prolonged period of time when compared to the 245 NA 165 Gly+ virus ( Fig 1B) . Plaque appearance, morphology and size was then assessed using 166 MDCK cells. Both viruses produced clear, distinct plaques ( Fig 1C) of similar size (Fig   167 1D ). This data indicates that while the 245 NA glycosylation does not impact virus 168 replication on immortalized MDCK-SIAT1 or MDCK cells, it has an adverse effect on 169 virus replication in hNEC cultures.
170
To understand how the addition of a N-linked glycosylation could impact virus 171 replication and protein function, a model of the N2 neuraminidase monomer was 172 generated with UCSF Chimera 3D modeling software. A similar N2 neuraminidase 173 strain (A/Tanzania/2010) was used to highlight key residues and add a complex N-174 linked glycan at position 245 (Fig 2A) 268 concentration of 1.3nm ( Fig 5A) . Using 229-1G03, we found this antibody was able to 269 neutralize both 245 NA Gly+ and 245 NA Gly-viruses, with an average concentration of 270 6.4nm and 1.5nm respectively, indicating somewhat reduced neutralizing activity 271 against the 245 NA Gly+ virus ( Fig 5B) . Using the experimentally determined 50%
272 neutralizing antibody concentration with the 245 NA Gly-virus in Fig5A and 5B, a 273 multistep growth curve in the presence or absence of these antibodies was performed.
274 Figure 5C demonstrates that the 245 NA Gly+ virus was not impacted with the 235-275 1C02 antibody, as no significant difference was found in infectious virus production 276 comparing human IgG isotype (clone IGHG1) and 235-1C02. However, antibody 229-277 1G03 did significantly decrease infectious virus production of the 245 NA Gly+ virus,
278 showing a partial ability to neutralize infectious virus, consistent with the binding (Fig 2) 279 and enzymatic inhibition results (Fig 4) . This suggests that the epitope this antibody 280 binds is partially accessible on the 245 NA Gly+ protein. In Figure 5D , both human 281 monoclonal antibodies significantly decreased infectious virus production of the 245 NA 
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The presence of a glycosylation site at NA 245 did not affect NA sensitivity to the 321 with an as yet undefined binding epitope is partially blocked from binding to their epitope 322 by this glycan (Fig 2, 4, 5 This study highlights the necessity to consider multiple aspects of the NA protein 368 in regard to vaccine production and virus evolution. Decades of influenza research have 369 focused on the HA protein for vaccine development, viral evolution and pandemic 370 potential. As the interest in NA protein as a vaccine increases, many of the lessons 371 learned studying influenza HA may also be applied to NA. The NA protein is 372 immunogenic and can provide protection against many strains of influenza viruses [41] .
373 However, like the HA protein, the NA protein can undergo antigenic drift and evade the 374 humoral immune response. As immune pressure mounts due to a renewed vaccination 375 effort at targeting NA protein, the NA protein will likely also become a "moving target" for 
